EMA Authorised: Iqirvo (Elafibranor) — Ipsen Pharma

View source ↗

Summary

Elafibranor (Iqirvo) by Ipsen Pharma has been authorised with conditional approval as an orphan medicine for liver cirrhosis and biliary diseases in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Disease
• Liver Cirrhosis

Drugs mentioned

• IQIRVO (ELAFIBRANOR)

Snippet

Status: Authorised. Therapeutic area: Liver Cirrhosis, Biliary. MAH: Ipsen Pharma. Decision date: 11/06/2026. Conditional approval. Orphan medicine